Scientific Evidence Mounts on Therapeutic Value of Psychedelics

June 11, 2021 12:05:09

Scientific evidence regarding the use of psychedelic substances as therapies for various mental conditions has been growing recently, with various studies on these substances being conducted.

For instance, the Johns Hopkins Center for Psychedelic and Consciousness Research, which is the biggest psychedelic research center globally, has been carrying out studies on substances such as psilocybin, MDMA and ketamine to evaluate whether they can be used as treatments for Alzheimer’s, post-traumatic stress disorder and depression.

Additionally, the University of Toronto is planning on conducting research on the use of psilocybin, which is the active ingredient found in magic mushrooms; the university is just waiting for approval from Health Canada.

Despite these discoveries, however, Dr. Gabor Maté, a distinguished addictions expert, notes that psychedelics are still far from being included as part of conventional health care. In an interview, Maté explained that the substances only occupied a small part of the approach to mental health conditions, as they were still illegal, adding that governments had made it challenging to conduct studies. Maté, who is an expert in childhood development, stress, addiction and trauma, revealed that in more than a decade working with these substances, he’s observed many positive results.

Despite this, however, he added that these positive results were not to be expected when the substances were administered in unsupervised conditions, noting that there were risks. He explained that the substances were to be administered in a proper hospital setting, under the supervision of trained professionals. He asserts that in comparison with the psychiatric medications normally prescribed to individuals who suffer from various mental conditions, psychedelics are much safer.

However, not everyone is of the same opinion. Dr. Pierre Blier, for instance, who has been conducting research on the use of ketamine in patients who suffer from treatment-resistant depression. A professor from the department of psychiatry at the University of Ottawa, Blier notes that individuals should be careful when looking for their own treatments, adding that purchasing drugs from an unregulated source may be dangerous.

Many patients who have not found the help they need from conventional medicines are still hopeful that psychedelics may in the near future be introduced as alternative therapies for conditions such as post-traumatic stress disorder, anxiety and depression.

Furthermore, some patients are travelling to countries such as Jamaica and Brazil, where many psychedelic clinics exist, to seek help. Instead of self-administering psychedelics that may have been obtained from nonregulated sources, these individuals have these substances administered under the supervision of health-care professionals, who follow up these sessions with therapy.

If this growing awareness turns into large-scale regulatory reforms, entities such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) that have ventured into this sector are likely to see plenty of demand for any approved therapeutic products they offer.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.